Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib
b'The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors.'